Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5793190 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1EPHX2TDP1 | |
| SCHEMBL19828807 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1EPHX2TDP1 | |
| SCHEMBL7096279 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1EPHX2TDP1 | |
| SCHEMBL905734 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1EPHX2TDP1 | |
| SCHEMBL10783106 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1EPHX2TDP1 | |
| SCHEMBL6387083 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1EPHX2TDP1 | |
| SCHEMBL7095353 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1EPHX2TDP1 | |
| SCHEMBL15561335 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1EPHX2TDP1 | |
| SCHEMBL15561344 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1EPHX2TDP1 | |
| SCHEMBL2364491 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1EPHX2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2026-04-16 | — | — | US | disclosed |
| CN-112105625-B | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | 赛诺菲 | 2024-12-31 | — | — | CN | disclosed |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2024-11-14 | — | — | US | disclosed |
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | SANOFI (FR) | 2024-02-13 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220372063-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2022-11-24 | — | — | US | disclosed |
| EP-4025582-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2022-07-13 | — | — | EP | disclosed |
| CN-114728999-A | Oligonucleotides containing nucleotide analogs | 赛诺菲 | 2022-07-08 | — | — | CN | disclosed |
| US-20210115075-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI (FR) | 2021-04-22 | — | — | US | disclosed |
| EP-1572067-A4 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS INC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-7491805-B2 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| WO-2007073489-A2 | MOLECULES FOR GENE DELIVERY AND GENE THERAPY, AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2007-06-28 | — | — | WO | disclosed |
| EP-1622572-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1572067-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005041859-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY. | SIRNA THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | RIBOZYME PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
| US-20030130186-A1 | Conjugates and compositions for cellular delivery | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2002094185-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | RNMT, RRM2B, RRM2 | ALDH1A1 1839/4885MAPK1 3273/4885L3MBTL1 425/4885 |
| US-20210115075-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, RRM2B, RRM2 | ALDH1A1 1839/4885MAPK1 3273/4885L3MBTL1 425/4885 |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | NSUN2, NSUN3, SNRPA | ALDH1A1 4264/4885MAPK1 3928/4885L3MBTL1 68/4885 |
| US-20030130186-A1 | Conjugates and compositions for cellular delivery | ALB, FUT5, RNGTT | ALDH1A1 1906/4885MAPK1 4038/4885L3MBTL1 1408/4885 |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | ALDH1A1 1406/4885MAPK1 4465/4885L3MBTL1 1500/4885 |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | ALDH1A1 1406/4885MAPK1 4465/4885L3MBTL1 1500/4885 |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, NSUN2, ADAR | ALDH1A1 3481/4885MAPK1 4441/4885L3MBTL1 195/4885 |
| US-20220372063-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | DCLRE1B, UPF1, IGF2BP1 | ALDH1A1 2953/4885MAPK1 4125/4885L3MBTL1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.